FDA grants fast track designation for vaccine-enhanced adoptive T cell therapy for glioblastoma
The U.S. Food and Drug Administration (FDA) has granted fast track designation to a vaccine-enhanced adoptive T cell therapy (VACT) for treatment of glioblastoma multiforme, according to a press release.
Phase 1 and 2a studies in multiple cancers, including glioblastoma, have demonstrated significant benefit when using TVAX Biomedical VACT.
“We are very pleased to receive Fast Track Designation by the FDA for glioblastoma multiforme (GBM),” stated Dr Wayne Carter, Chief Executive Officer in a press release. “Glioblastoma is a devastating disease for which there are limited treatment options.”